The ins and outs of calcium signalling in lactation and involution: implications for breast cancer treatment by Davis, Felicity M.
Accepted Manuscript
Title: The ins and outs of calcium signalling in lactation and
involution: implications for breast cancer treatment
Author: Felicity M. Davis
PII: S1043-6618(16)31307-X
DOI: http://dx.doi.org/doi:10.1016/j.phrs.2016.12.007
Reference: YPHRS 3430
To appear in: Pharmacological Research
Received date: 21-4-2016
Revised date: 31-10-2016
Accepted date: 7-12-2016
Please cite this article as: Davis Felicity M.The ins and outs of calcium signalling
in lactation and involution: implications for breast cancer treatment.Pharmacological
Research http://dx.doi.org/10.1016/j.phrs.2016.12.007
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
	 1
The ins and outs of calcium signalling in lactation and involution: implications for breast 
cancer treatment 
 
Felicity M. Davis1,2* 
 
1School of Pharmacy, The University of Queensland, Brisbane, Australia, 4102  
2Mater Research Institute, The University of Queensland Translational Research Institute, 
Brisbane, Australia, 4102 
 
*Correspondence: Felicity Davis, f.davis@uq.edu.au 
 
  
	 2
Graphical abstract 
 
 
Abstract 
The mammary epithelium is highly responsive to hormonal and non-hormonal signalling cues for physiological 
growth, function and tissue remodelling. Whilst steroid hormones freely diffuse across the cell membrane to bind 
to intracellular hormone receptors, cell-impermeable ligands, including many peptide hormones, growth factors 
and cytokines, bind to receptors on the plasma membrane and relay their message via the specific activation of 
intracellular signal transduction pathways. A signalling pathway that is indispensable for decoding many 
extracellular signals into cellular responses is calcium (Ca2+). Changes in the expression of specific Ca2+ channels, 
pumps and binding proteins may therefore greatly alter the nature of the cellular response to various growth, 
morphogenetic and cell death stimuli. This review summarises changes in the expression, localisation and 
function of key Ca2+ channels and pumps in mammary epithelial cells during lactation and discusses how this 
altered Ca2+ handling may later expose these cells to targeted cell death during post-lactational involution. A 
greater understanding of the processes regulating the growth, death and regeneration of the mammary epithelium 
under physiological conditions may provide important insights into the proliferation and survival mechanisms 
underpinning malignant growth. The therapeutic manipulation of specific calcium signalling pathways in breast 
cancer cells to control aberrant cell proliferation and/or turnover represents an aim for the future. 
Keywords: Lactation; involution; mammary gland; Ca2+ channels and pumps; store-operated calcium entry. 
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Introduction 
The adult mammary gland is composed of a bifurcating and bilayered ductal tree embedded within an 
adipocyte-rich stroma. Two distinct epithelial cell types are present in the mammary gland: luminal epithelial 
cells line the lumen of each duct and are surrounded by a layer of basal (myoepithelial) cells in contact with the 
basement membrane [1,2]. After puberty, these cells remain largely quiescent, with some proliferation producing 
small alveolar buds in response to cyclical ovarian stimulation [3]. However, during pregnancy mammary 
epithelial cells rapidly proliferate to form lobuloalveolar structures that are able to produce and expel milk for 
neonatal nourishment. Once lactation is complete, the mammary gland regresses to a nulliparous-like state, 
capable of sustaining further cycles of growth, secretion and cell death with subsequent pregnancies [1,4]. The 
complete elimination of the alveolar epithelium during post-lactational involution is a major cell death event in 
mammals [5], and it is not yet understood how ductal epithelial cells and putative alveolar stem cells evade this 
cell death programme. The remarkable capacity of the mammary epithelium to reinstate a proliferative 
programme and to selectively regulate cell death under physiological conditions may provide important insights 
into the proliferation and survival mechanisms that support malignant growth. 
Post-lactational involution of the mammary gland occurs in two distinct phases: an early, reversible phase 
and a late, remodelling phase [5,6]. The first phase of involution is characterised by milk stasis and the STAT3-
dependent conversion of luminal alveolar cells from a secretory to a phagocytic phenotype [7,8]. The reuptake of 
milk fat globules (MFGs) and their delivery to and degradation by lysosomes results in lysosomal membrane 
permeabilisation and the subsequent leakage of cathepsin proteases into the cytosol [7]. In addition to the release 
of these executioner proteases, lysosomal membrane permeabilisation in phagocytic mammary epithelial cells 
could also dramatically elevate cytosolic Ca2+ levels. Resting cytosolic Ca2+ concentrations are tightly regulated 
at sub-micromolar levels [9]. By comparison, milk contains approximately 8 mM and 60 mM Ca2+ in humans and 
mice, respectively [10]. Thus, the reabsorption of secreted milk and the uncontrolled release of milk Ca2+ into the 
cytoplasm of luminal epithelial cells may deliver a secondary cell death signal (Fig. 1). Moreover, Ca2+ may also 
play a key role in the signalling events that instigate the switch from lactation to involution. This review discusses 
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key basolateral and apical pathways involved in the fortification of milk with Ca2+ during lactation and 
investigates how this Ca2+ signalling toolkit may later expose these cells to programmed cell death, providing a 
basis for the targeted removal of the alveolar epithelium during mammary gland involution.  
Basolateral Ca2+ entry  
The dramatic expansion of the mammary epithelium during pregnancy is accompanied by marked 
angiogenic growth, such that by parturition networks of capillaries envelope each alveolus, providing luminal 
cells with an ample source of Ca2+ and other nutrients for milk production (Fig. 2) [11]. Until recently, the identity 
of the Ca2+ channels responsible for Ca2+ entry across the basolateral (blood-facing) membrane of luminal 
secretory cells during lactation was not known [12–15]. In 2011, McAndrew et al. demonstrated that the then 
newly-identified store-operated Ca2+ channel pore-forming subunit Orai1 was significantly up-regulated in 
mammary tissue of lactating mice, and postulated that this Ca2+ influx channel was responsible for the passage of 
Ca2+ ions into luminal epithelial cells during lactation [13]. This study also revealed that ORAI1 mRNA levels 
were elevated in human breast cancer cell lines, indicating that ORAI1-mediated Ca2+ influx not only regulates 
processes important for the physiological function of mammary epithelial cells, but that these channels may also 
drive malignant cell behaviours. This work provided the impetus for in vivo milking studies using transgenic mice 
with targeted disruption of Orai1. These analyses confirmed that ORAI1 is critically important for milk Ca2+ 
enrichment, transporting more than half of milk Ca2+ across the basolateral membrane (Fig. 1a) [15]. These studies 
also revealed an essential role for ORAI1 in oxytocin-mediated contractility of basal epithelial cells, a process 
essential for milk ejection [15]. 
An important question is whether ORAI1 is principally activated in a store-dependent or independent 
manner in luminal epithelial cells during lactation. Store-operated Ca2+ entry through ORAI channels is activated 
in response to endoplasmic reticulum (ER) Ca2+ store depletion. This may occur, for example, by receptor-
mediated activation of phospholipase C (PLC) [16]. PLC hydrolyses the membrane phospholipid 
phosphatidylinositol 4,5-bisphosphate (PIP2), producing inositol 1,4,5-trisphosphate (IP3), which binds to and 
activates IP3 receptor Ca2+ channels on the ER; depleted ER Ca2+ levels are then detected by the ER Ca2+ sensor 
STIM1, which activates Ca2+ influx through plasma membrane ORAI channels [17–22]. However, ORAI1 can 
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also be activated independently of STIM1 and the filling state of intracellular Ca2+ stores. Alternative mechanisms 
for ORAI1 channel opening include activation by STIM2 [23] and the Golgi Ca2+ pump secretory pathway Ca2+ 
ATPase (SPCA) 2 [24], as well as by arachadonic acid (ORAI1/3 heteromultimers) [25]. Indeed, non-stimulated 
Ca2+ influx has been observed in 2D and 3D mammary culture models, with evidence in support of both SPCA2- 
[14] and STIM2- [26] dependent modes of activation reported. A definitive demonstration of the mechanisms 
underpinning ORAI1 activation in luminal epithelial cells during lactation awaits milking studies using SPCA2, 
STIM2 and STIM1 mammary-specific knockout mice.  
Another important question is whether ORAI1-mediated Ca2+ signals participate in the involution switch. 
The transition from lactation to involution is initiated by the cessation of suckling; however, the molecular trigger 
for this phenotypic conversion has not been conclusively identified [5]. Leukaemia inhibitory factor (LIF) [27,28], 
transforming growth factor β-3 (TGFβ-3) [29] and serotonin have all been proposed as potential candidates [30]. 
LIF and serotonin receptors are known to activate PLC [31,32], and are thus likely to signal through store-operated 
Ca2+ entry in luminal cells during involution. It is therefore tempting to speculate that ORAI1 channels are up-
regulated on the basolateral membrane during lactation to facilitate constitutive, store-independent Ca2+ entry for 
milk Ca2+ enrichment, and that these channels later enhance and/or spatially-regulate store-operated Ca2+ entry 
responses to involution cues (Fig. 1b). Thus, Ca2+ influx may participate in the coordinated activation of 
intracellular signal transduction pathways important for initiating targeted cell death in the mammary gland. 
Indeed, signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa B (NFKB), two key 
involution signalling proteins, have previously been shown to be highly regulated by  calcium signalling 
microdomains in breast cancer cells and neuronal cultures, respectively [33,34]. Further studies are required to 
determine whether these proteins are also regulated by spatially-restricted calcium signals in mammary epithelial 
cells during involution. 
Deciphering the precise in vivo role of ORAI1 and its activators in milk Ca2+ enrichment and involution 
signalling necessitates their specific genetic manipulation in luminal epithelial cells, e.g., using BLG-Cre [35] or 
WAP-Cre [36] mouse models to direct Cre-recombinase expression to the luminal cell lineage for targeted gene 
disruption. The complex roles for ORAI1 channels in the mammary gland cannot currently be unravelled using 
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pharmacological approaches, given that ORAI1-mediated Ca2+ entry is also essential for milk ejection by 
mammary myoepithelial cells [15]. Nevertheless, important information regarding the roles of these channels and 
their activators during involution can be garnered by the genetic and pharmacological modulation of ORAI1 
channel function in luminal cell culture models.  
The therapeutic targeting of ORAI1 channels is an area of intense investigation. Many of the 
pharmacological agents that have traditionally been used to block store-operated Ca2+ entry in cell culture and/or 
rodent models, e.g., the lanthanides (Gd3+ and La3+) and 2-aminoethyldiphenyl borinate (2-APB), do so non-
specifically [37]. For example, lanthanides inhibit store-operated Ca2+ entry channels in the sub-micromolar 
range, but also inhibit voltage-gated Ca2+ channels (> 1 μM), transient receptor potential canonical (TRPC) 
channels (~100 μM) and Ca2+ ATPases (> 1 mM). The pharmacological utility of the lanthanides is also limited 
by their poor solubility in media containing serum or phosphate buffers [37].  The pharmacology of 2-APB in 
blocking store-operated Ca2+ entry is also highly complex, with differential modes of inhibition and activation, 
dependent on the concentration of 2-APB and the channel isoform expressed [37–41]. More recently, new 
inhibitors of ORAI1 calcium channels have been described, e.g., AMG-1 (Amgen), and have been successfully 
used to target T-cell mediated autoimmune diseases in mice [42]. Further work is required to determine the role 
of ORAI1 Ca2+ channels in the targeted cell death of the alveolar epithelium during involution, and whether the 
elevated expression of this channel in certain breast cancers [13,43] could be exploited in a similar manner for 
the treatment of breast cancer.  
Apical Ca2+ efflux  
Plasma membrane Ca2+ ATPases (PMCAs) are a family of P-type Ca2+ pumps that extrude Ca2+ from the 
cytosol and play an integral role in epithelial Ca2+ homeostasis and signalling [44]. Four PMCA isoforms are 
expressed in mammals (PMCA1-4). These pumps are characterised by a long C-terminal tail, comprising a 
calmodulin (CaM)-binding domain [44,45]. In the absence of CaM, the CaM-binding domain binds to and self-
inhibits pump activity [44]. Whilst PMCA4 and PMCA1 are ubiquitously expressed, the latter being essential for 
life [46], PMCA2 and PMCA3 have a more restricted tissue distribution. PMCA2 is dramatically upregulated in 
the mammary epithelium during pregnancy and lactation [47–49], where it is constantly shed into the milk via 
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secretory exocytosis and replenished with newly synthesised protein [12,48]. This Ca2+ pump displays fast Ca2+ 
stimulation kinetics and is highly active in the absence of calmodulin, enabling the rapid and persistent efflux of 
Ca2+ across the apical membrane of mammary epithelial cells during lactation [45,50,51]. Indeed, in vivo milking 
studies in Pmca2 null mice have revealed that this Ca2+ ATPase is responsible for 60-70% of milk Ca2+ transport 
across the apical membrane (Fig. 1a) [49,51]. 
 PMCA2 expression is rapidly downregulated during involution (Fig. 1b) [49,52,53]. Elegant experiments 
to induce milk stasis and involution in mice by teat sealing have revealed significant reductions in PMCA2 protein 
levels as early as four hours post-sealing [52]. Importantly, no changes in PMCA2 expression were observed in 
the contralateral (unsealed) mammary glands, suggesting that the mechanism by which PMCA2 is downregulated 
during involution is governed by local factors. PMCA2 levels continue to decline during the early phase of 
involution and are barely detectable after 24 hours. The sudden and dramatic loss of this major Ca2+ extrusion 
pathway in mammary epithelial cells is likely to result in an increase in their basal cytosolic Ca2+ concentration 
[53,54]. 
 An increase in cytosolic Ca2+ levels in luminal epithelial cells during involution is thought to activate 
cytosolic calpains (CAPNs) [52,54]. A role for CAPNs in post-lactational involution has been demonstrated 
pharmacologically in mice that were administered the cell-permeable CAPN inhibitor calpeptin during involution 
[54]. CAPN1 and -2 are cysteine proteases that are activated by micromolar and millimolar Ca2+ concentrations, 
respectively. Capn1 and -2 mRNA levels are increased within 24 hours of involution, and CAPN protease activity 
is increased by 24-48 hours [52,54]. CAPN activity is also increased within the lysosomal compartment during 
involution, where it has been suggested to contribute to lysosomal destabilisation [54]. The re-uptake of milk 
during mammary involution and the CAPN- and/or MFG-dependent release of milk Ca2+ from lysosomes may 
further augment cytosolic CAPN activity, reinforcing this cell death cascade. In this context, it is important to 
note that calpeptin also inhibits the lysosomal protease cathepsin L [55], which is expressed early in involution 
and is also suspected to play an important role in this process [8]. Thus, further studies in this area are required to 
delineate these pathways in post-lactational involution and their calcium dependence.  
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 In addition to its role in regulating physiological cell death in the mammary gland, PMCA2 has been 
proposed as a therapeutic target in breast cancer [52,56–60]. Overexpression of PMCA2 in T47D breast cancer 
cells protects against Ca2+-induced CAPN activation and cell death [52]. Additionally, PMCA2 has been shown 
to regulate HER2 localisation and signalling in HER2 positive breast cancer cells [56]. Whilst various pan-PMCA 
inhibitors have been used to experimentally block PMCA activity, e.g., La3+, orthovanadate and carboxyeosin, 
these compounds display off-target effects and are not isoform-selective. A significant challenge in the 
development of PMCA inhibitors arises from the limited access to these pumps from the outside of the cell, with 
the majority of their protein mass located intracellularly [61]. Nevertheless, with improved structural information 
and the emergence of new avenues for biological therapies, the selective targeting of PMCAs may one day offer 
a pathway forward in the treatment of breast cancer. 
Conclusion 
Most women will experience one or more pregnancies in their lifetime. This extraordinary biological event 
is associated with the recruitment of mammary alveolar stem/progenitor cells; invasive growth and remodelling 
of the mammary epithelium; marked angiogenesis; and ultimately coordinated cell death of the alveolar 
epithelium. However, our understanding of the fundamental processes regulating the growth, death and 
regeneration of this organ are incomplete, despite its parallels to breast cancer. This review discussed the calcium 
ion as essential cargo for secretory cells during lactation, and subsequently outlined mechanisms by which the 
expression signature of Ca2+ channels and pumps in the alveolar epithelium during lactation may specifically 
expose these cells to programmed cell death during post-lactational involution. The pharmaceutical mimicry of 
Ca2+-mediated cell death in breast cancer cells, which exhibit remarkably similar changes in Ca2+ signalling 
proteins, may represent a new era in the therapeutic targeting of this pervasive disease. 
Acknowledgements 
FD was funded by a National Health and Medical Research Council (NHMRC) CJ Martin Early Career 
Fellowship (GNT1071074). Thanks to Drs James Putney, Gregory Monteith and Christopher Campos for their 
valuable feedback on this manuscript. 
 
	 9
References 
[1] C.J. Watson, W.T. Khaled, Mammary development in the embryo and adult: a journey of morphogenesis 
and commitment, Development. 135 (2008) 995–1003. doi:10.1242/dev.005439. 
[2] J.E. Visvader, J. Stingl, Mammary stem cells and the differentiation hierarchy: current status and 
perspectives, Genes Dev. 28 (2014) 1143–1158. doi:10.1101/gad.242511.114. 
[3] M.D. Sternlicht, Key stages in mammary gland development: the cues that regulate ductal branching 
morphogenesis, Breast Cancer Res. 8 (2006) 201. doi:10.1186/bcr1368. 
[4] R. van Amerongen, A.N. Bowman, R. Nusse, Developmental stage and time dictate the fate of Wnt/β-
catenin-responsive stem cells in the mammary gland, Cell Stem Cell. 11 (2012) 387–400. 
doi:10.1016/j.stem.2012.05.023. 
[5] C.J. Watson, P.A. Kreuzaler, Remodeling mechanisms of the mammary gland during involution, Int. J. 
Dev. Biol. 55 (2011) 757–762. doi:10.1387/ijdb.113414cw. 
[6] L.R. Lund, J. Rømer, N. Thomasset, H. Solberg, C. Pyke, M.J. Bissell, K. Danø, Z. Werb, Two distinct 
phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways, 
Development. 122 (1996) 181–93. doi:10.1111/j.1600-6143.2008.02497.x.Plasma. 
[7] T.J. Sargeant, B. Lloyd-Lewis, H.K. Resemann, A. Ramos-Montoya, J. Skepper, C.J. Watson, Stat3 
controls cell death during mammary gland involution by regulating uptake of milk fat globules and 
lysosomal membrane permeabilization, Nat. Cell Biol. 16 (2014) 1057–68. doi:10.1038/ncb3043. 
[8] P.A. Kreuzaler, A.D. Staniszewska, W. Li, N. Omidvar, B. Kedjouar, J. Turkson, V. Poli, R.A. Flavell, 
R.W.E. Clarkson, C.J. Watson, Stat3 controls lysosomal-mediated cell death in vivo, Nat. Cell Biol. 13 
(2011) 303–9. doi:10.1038/ncb2171. 
[9] M.J. Berridge, P. Lipp, M.D. Bootman, The versatility and universality of calcium signalling, Nat. Rev. 
Mol. Cell Biol. 1 (2000) 11–21. doi:10.1038/35036035. 
[10] M.C. Neville, Calcium secretion into milk, J. Mammary Gland Biol. Neoplasia. 10 (2005) 119–128. 
doi:10.1007/s10911-005-5395-z. 
[11] V. Djonov, A.C. Andres, A. Ziemiecki, Vascular remodelling during the normal and malignant life cycle 
	 10
of the mammary gland, Microsc. Res. Tech. 52 (2001) 182–189. doi:10.1002/1097-
0029(20010115)52:2<182::AID-JEMT1004>3.0.CO;2-M. 
[12] W.J. Lee, G.R. Monteith, S.J. Roberts-Thomson, Calcium transport and signaling in the mammary gland: 
targets for breast cancer, Biochim. Biophys. Acta - Rev. Cancer. 1765 (2006) 235–255. 
doi:10.1016/j.bbcan.2005.12.001. 
[13] D. McAndrew, D.M. Grice, A.A. Peters, F.M. Davis, T. Stewart, M. Rice, C.E. Smart, M.A. Brown, P.A. 
Kenny, S.J. Roberts-Thomson, G.R. Monteith, ORAI1-mediated calcium influx in lactation and in breast 
cancer, Mol. Cancer Ther. 10 (2011) 448–460. doi:10.1158/1535-7163.MCT-10-0923. 
[14] B.M. Cross, A. Hack, T.A. Reinhardt, R. Rao, SPCA2 regulates Orai1 trafficking and store independent 
Ca2+ entry in a model of lactation, PLoS One. 8 (2013). doi:10.1371/journal.pone.0067348. 
[15] F.M. Davis, A. Janoshazi, K.S. Janardhan, N. Steinckwich, D.M. D’Agostin, J.G. Petranka, P.N. Desai, 
S.J. Roberts-Thomson, G.S. Bird, D.K. Tucker, S.E. Fenton, S. Feske, G.R. Monteith, J.W. Putney, 
Essential role of Orai1 store-operated calcium channels in lactation, Proc. Natl. Acad. Sci. U. S. A. 112 
(2015) 5827–32. doi:10.1073/pnas.1502264112. 
[16] J.T. Smyth, S.Y. Hwang, T. Tomita, W.I. DeHaven, J.C. Mercer, J.W. Putney, Activation and regulation 
of store-operated calcium entry, J. Cell. Mol. Med. 14 (2010) 2337–2349. doi:10.1111/j.1582-
4934.2010.01168.x. 
[17] P.G. Hogan, A. Rao, Store-operated calcium entry: mechanisms and modulation, Biochem. Biophys. Res. 
Commun. 460 (2015) 40–49. doi:10.1016/j.bbrc.2015.02.110. 
[18] J. Roos, P.J. DiGregorio, A. V. Yeromin, K. Ohlsen, M. Lioudyno, S. Zhang, O. Safrina, J.A. Kozak, 
S.L. Wagner, M.D. Cahalan, G. Veli??elebi, K.A. Stauderman, STIM1, an essential and conserved 
component of store-operated Ca2+ channel function, J. Cell Biol. 169 (2005) 435–445. 
doi:10.1083/jcb.200502019. 
[19] J. Liou, M.L. Kim, D.H. Won, J.T. Jones, J.W. Myers, J.E. Ferrell, T. Meyer, STIM is a Ca2+ sensor 
essential for Ca2+-store- depletion-triggered Ca2+ influx, Curr. Biol. 15 (2005) 1235–1241. 
doi:10.1016/j.cub.2005.05.055. 
	 11
[20] S.L. Zhang, A. V Yeromin, X.H.-F. Zhang, Y. Yu, O. Safrina, A. Penna, J. Roos, K. a Stauderman, M.D. 
Cahalan, Genome-wide RNAi screen of Ca2+ influx identifies genes that regulate Ca(2+) release-
activated Ca(2+) channel activity, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9357–9362. 
doi:10.1073/pnas.0603161103. 
[21] S. Feske, Y. Gwack, M. Prakriya, S. Srikanth, S.-H. Puppel, B. Tanasa, P.G. Hogan, R.S. Lewis, M. 
Daly, A. Rao, A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function, 
Nature. 441 (2006) 179–185. doi:10.1038/nature04702. 
[22] M. Vig, C. Peinelt, A. Beck, D.L. Koomoa, D. Rabah, M. Koblan-Huberson, S. Kraft, H. Turner, A. 
Fleig, R. Penner, J.-P. Kinet, CRACM1 is a plasma membrane protein essential for store-operated Ca2+ 
entry, Science. 312 (2006) 1220–1223. doi:10.1126/science.1127883. 
[23] O. Brandman, J. Liou, W.S. Park, T. Meyer, STIM2 is a feedback regulator that stabilizes basal cytosolic 
and endoplasmic reticulum Ca2+ levels, Cell. 131 (2007) 1327–1339. doi:10.1016/j.cell.2007.11.039. 
[24] M. Feng, D.M. Grice, H.M. Faddy, N. Nguyen, S. Leitch, Y. Wang, S. Muend, P.A. Kenny, S. Sukumar, 
S.J. Roberts-Thomson, G.R. Monteith, R. Rao, Store-independent activation of orai1 by SPCA2 in 
mammary tumors, Cell. 143 (2010) 84–98. doi:10.1016/j.cell.2010.08.040. 
[25] J.L. Thompson, T.J. Shuttleworth, Exploring the unique features of the ARC channel, a store-
independent orai channel, Channels. 7 (2013) 364–373. doi:10.4161/chan.26156. 
[26] D.G.F. Ross, C.E. Smart, I. Azimi, S.J. Roberts-Thomson, G.R. Monteith, Assessment of ORAI1-
mediated basal calcium influx in mammary epithelial cells, BMC Cell Biol. 14 (2013) 57. 
doi:10.1186/1471-2121-14-57. 
[27] C. Schere-Levy, V. Buggiano, A. Quaglino, A. Gattelli, M.C. Cirio, I. Piazzon, S. Vanzulli, E.C. Kordon, 
Leukemia inhibitory factor induces apoptosis of the mammary epithelial cells and participates in mouse 
mammary gland involution, Exp Cell Res. 282 (2003) 35–47. doi:S0014482702956661 [pii]. 
[28] E. a Kritikou, A. Sharkey, K. Abell, P.J. Came, E. Anderson, R.W.E. Clarkson, C.J. Watson, A dual, 
non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary 
gland, Development. 130 (2003) 3459–68. doi:10.1242/dev.00578. 
	 12
[29]  a V Nguyen, J.W. Pollard, Transforming growth factor beta3 induces cell death during the first stage of 
mammary gland involution, Development. 127 (2000) 3107–3118. 
[30] M. Matsuda, T. Imaoka, A.J. Vomachka, G.A. Gudelsky, Z. Hou, M. Mistry, J.P. Bailey, K.M. Nieport, 
D.J. Walther, M. Bader, N.D. Horseman, Serotonin regulates mammary gland development via an 
autocrine-paracrine loop, Dev. Cell. 6 (2004) 193–203. doi:10.1016/S1534-5807(04)00022-X. 
[31] T.G. Boulton, N. Stahl, G.D. Yancopoulos, Ciliary neurotrophic factor/leukemia inhibitory 
factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set 
of proteins overlapping those induced by other cytokines and growth factors, J. Biol. Chem. 269 (1994) 
11648–11655. 
[32] J.R. Raymond, Y. V Mukhin, A. Gelasco, J. Turner, G. Collinsworth, T.W. Gettys, J.S. Grewal, M.N. 
Garnovskaya, Multiplicity of mechanisms of serotonin receptor signal transduction, Pharmacol. Ther. 92 
(2001) 179–212. doi:10.1016/S0163-7258(01)00169-3. 
[33] F.M. Davis, I. Azimi, R. a Faville,  a a Peters, K. Jalink, J.W. Putney, G.J. Goodhill, E.W. Thompson, 
S.J. Roberts-Thomson, G.R. Monteith, Induction of epithelial-mesenchymal transition (EMT) in breast 
cancer cells is calcium signal dependent, Oncogene. 33 (2013) 2307–2316. doi:10.1038/onc.2013.187. 
[34] M.K. Meffert, J.M. Chang, B.J. Wiltgen, M.S. Fanselow, D. Baltimore, NF-kappa B functions in synaptic 
signaling and behavior, Nat Neurosci. 6 (2003) 1072–1078. doi:10.1038/nn1110. 
[35] S. Selbert, D.J. Bentley, D.W. Melton, D. Rannie, P. Lourenço, C.J. Watson, A.R. Clarke, Efficient 
BLG-Cre mediated gene deletion in the mammary gland, Transgenic Res. 7 (1998) 387–396. 
doi:10.1023/A:1008848304391. 
[36] K.U. Wagner, R.J. Wall, L. St-Onge, P. Gruss, A. Wynshaw-Boris, L. Garrett, M. Li, P.A. Furth, L. 
Hennighausen, Cre-mediated gene deletion in the mammary gland, Nucleic Acids Res. 25 (1997) 4323–
4330. doi:10.1093/nar/25.21.4323. 
[37] J.W. Putney, Pharmacology of store-operated calcium channels, Mol. Interv. 10 (2010) 209–18. 
doi:10.1124/mi.10.4.4. 
[38] M. Prakriya, R.S. Lewis, Potentiation and inhibition of Ca2+ release-activated Ca2+ channels by 2-
	 13
aminoethyldiphenyl borate (2-APB) occurs independently of IP3 receptors, J. Physiol. 536 (2001) 3–19. 
doi:10.1111/j.1469-7793.2001.t01-1-00003.x. 
[39] H.T. Ma, K. Venkatachalam, J.B. Parys, D.L. Gill, Modification of store-operated channel coupling and 
inositol trisphosphate receptor function by 2-aminoethoxydiphenyl borate in DT40 lymphocytes, J. Biol. 
Chem. 277 (2002) 6915–6922. doi:10.1074/jbc.M107755200. 
[40] W.I. DeHaven, J.T. Smyth, R.R. Boyles, G.S. Bird, J.W. Putney, Complex actions of 2-
aminoethyldiphenyl borate on store-operated calcium entry, J. Biol. Chem. 283 (2008) 19265–19273. 
doi:10.1074/jbc.M801535200. 
[41] R. Schindl, J. Bergsmann, I. Frischauf, I. Derler, M. Fahrner, M. Muik, R. Fritsch, K. Groschner, C. 
Romanin, 2-Aminoethoxydiphenyl borate alters selectivity of Orai3 channels by increasing their pore 
size, J. Biol. Chem. 283 (2008) 20261–20267. doi:10.1074/jbc.M803101200. 
[42] U. Kaufmann, P.J. Shaw, L. Kozhaya, R. Subramanian, K. Gaida, D. Unutmaz, H.J. McBride, S. Feske, 
Selective ORAI1 inhibition ameliorates autoimmune central nervous system inflammation by 
suppressing effector but not regulatory T cell function, J. Immunol. 196 (2016) 573–85. 
[43] R.K. Motiani, I.F. Abdullaev, M. Trebak, A novel native store-operated calcium channel encoded by 
Orai3: Selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen 
receptor-negative breast cancer cells, J. Biol. Chem. 285 (2010) 19173–19183. 
doi:10.1074/jbc.M110.102582. 
[44] R. Lopreiato, M. Giacomello, E. Carafoli, The plasma membrane calcium pump: new ways to look at an 
old enzyme, J. Biol. Chem. 289 (2014) 10261–8. doi:10.1074/jbc.O114.555565. 
[45] M. Brini, T. Calì, D. Ottolini, E. Carafoli, The plasma membrane calcium pump in health and disease, 
FEBS J. 280 (2013) 5385–97. doi:10.1111/febs.12193. 
[46] G.W. Okunade, M.L. Miller, G.J. Pyne, R.L. Sutliff, K.T. O’Connor, J.C. Neumann, A. Andringa, D.A. 
Miller, V. Prasad, T. Doetschman, R.J. Paul, G.E. Shull, Targeted ablation of plasma membrane Ca2+-
ATPase (PMCA) 1 and 4 indicates a major housekeeping function for PMCA1 and a critical role in 
hyperactivated sperm motility and male fertility for PMCA4, J. Biol. Chem. 279 (2004) 33742–50. 
	 14
[47] T.A. Reinhardt, R.L. Horst, Ca2+-ATPases and their expression in the mammary gland of pregnant and 
lactating rats, Am. J. Physiol. 276 (1999) C796–C802. 
[48] T.A. Reinhardt, A.G. Filoteo, J.T. Penniston, R.L. Horst, Ca(2+)-ATPase protein expression in mammary 
tissue, Am. J. Physiol. Cell Physiol. 279 (2000) C1595–C1602. 
[49] J.N. VanHouten, M.C. Neville, J.J. Wysolmerski, The calcium-sensing receptor regulates plasma 
membrane calcium adenosine triphosphatase isoform 2 activity in mammary epithelial cells: A 
mechanism for calcium-regulated calcium transport into milk, Endocrinology. 148 (2007) 5943–5954. 
doi:10.1210/en.2007-0850. 
[50] N.L. Elwess, A.G. Filoteo, A. Enyedi, J.T. Penniston, Plasma membrane Ca2+ pump isoforms 2a and 2b 
are unusually responsive to calmodulin and Ca2+, J. Biol. Chem. 272 (1997) 17981–17986. 
doi:10.1074/jbc.272.29.17981. 
[51] T.A. Reinhardt, J.D. Lippolis, G.E. Shull, R.L. Horst, Null mutation in the gene encoding plasma 
membrane Ca2+-ATPase isoform 2 impairs calcium transport into milk, J. Biol. Chem. 279 (2004) 
42369–42373. doi:10.1074/jbc.M407788200. 
[52] J. VanHouten, C. Sullivan, C. Bazinet, T. Ryoo, R. Camp, D.L. Rimm, G. Chung, J. Wysolmerski, 
PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer, 
Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 11405–11410. doi:10.1073/pnas.0911186107. 
[53] T.A. Reinhardt, J.D. Lippolis, Mammary gland involution is associated with rapid down regulation of 
major mammary Ca2+-ATPases, Biochem. Biophys. Res. Commun. 378 (2009) 99–102. 
doi:10.1016/j.bbrc.2008.11.004. 
[54] T. Arnandis, I. Ferrer-Vicens, E.R. García-Trevijano, V.J. Miralles, C. García, L. Torres, J.R. Viña, R. 
Zaragozá, Calpains mediate epithelial-cell death during mammary gland involution: mitochondria and 
lysosomal destabilization, Cell Death Differ. 19 (2012) 1536–48. doi:10.1038/cdd.2012.46. 
[55] T. Sasaki, M. Kishi, M. Saito, T. Tanaka, N. Higuchi, E. Kominami, N. Katunuma, T. Murachi, 
Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins., J. Enzyme Inhib. 3 (1990) 
195–201. doi:10.3109/14756369009035837. 
	 15
[56] J. Jeong, J. VanHouten, P. Dann, W. Kim, C. Sullivan, H. Yu, L. Liotta, V. Espina, S. DF, P. Friedman, 
J. Wysolmerski, PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-
mediated breast cancer, Proc. Natl. Acad. Sci. U. S. A. 113 (2016) E282-90. 
[57] W.J. Lee, S.J. Roberts-Thomson, G.R. Monteith, Plasma membrane calcium-ATPase 2 and 4 in human 
breast cancer cell lines, Biochem. Biophys. Res. Commun. 337 (2005) 779–783. 
doi:10.1016/j.bbrc.2005.09.119. 
[58] B.M. Cross, G.E. Breitwieser, T. a Reinhardt, R. Rao, Cellular calcium dynamics in lactation and breast 
cancer: from physiology to pathology, Am. J. Physiol. Cell Physiol. (2013). 
doi:10.1152/ajpcell.00330.2013. 
[59] G.R. Monteith, F.M. Davis, S.J. Roberts-Thomson, Calcium channels and pumps in cancer: Changes and 
consequences, J. Biol. Chem. 287 (2012) 31666–31673. doi:10.1074/jbc.R112.343061. 
[60] S.J. Roberts-Thomson, M.C. Curry, G.R. Monteith, Plasma membrane calcium pumps and their 
emerging roles in cancer, World J. Biol. Chem. 1 (2010) 248–53. doi:10.4331/wjbc.v1.i8.248. 
[61] E.E. Strehler, Plasma membrane calcium ATPases as novel candidates for therapeutic agent 
development, J. Pharm. Pharm. Sci. 16 (2013) 190–206. 
 
  
	 16
Figure Legends 
Fig. 1: An overview of Ca2+ signalling in lactation and involution. a, Ca2+ transport in mouse alveolar luminal 
cells during lactation. Ca2+ is transported across the basolateral membrane by ORAI1 Ca2+ channels (i). Whilst 
some Ca2+ may enter the secretory pathway (ii), the majority of milk Ca2+ is transported across the apical 
membrane by PMCA2 (iii). b, Proposed mechanisms by which altered Ca2+ handling in alveolar luminal cells 
may participate in post-lactational involution. Ca2+ signalling may be a key signal transduction pathway in the 
involution signalling cascade, potentially acting downstream of PLC-coupled cell surface receptors (i). The 
reduction in PMCA2 expression during the early phase of involution may elevate intracellular Ca2+ levels and 
activate CAPNs (ii). Luminal epithelial cells switch to a phagocytic phenotype during involution. The reuptake 
of milk, a Ca2+-rich fluid, and its trafficking to the lysosomal compartment may drastically increase cytosolic 
Ca2+ levels following involution-associated lysosomal membrane permeabilisation (iii). Ca2+, calcium; [Ca2+]milk, 
milk Ca2+ concentration; [Ca2+]cyt, cytosolic Ca2+ concentration; [Ca2+]serum, serum Ca2+ concentration; Ctps, 
cathepsin proteases; ER, endoplasmic reticulum; IP3, inositol 1,4,5-trisphosphate; MFG, milk fat globule; NFKB, 
nuclear factor kappa B; PLC, phospholipase C; PMCA2, plasma membrane Ca2+ ATPase 2; R, receptor; pSTAT, 
phosphorylated signal transducer and activator of transcription; SPCA, secretory pathway Ca2+ ATPase; STIM, 
stromal interaction molecule.  
 
Fig. 2: Scanning electron microscopy (SEM) imaging of an alveoli from a lactating mouse mammary. L, 
luminal epithelial cell; M, myoepithelial cell; BV, blood vessel.   
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